/
Oncology
Thyroid Carcinoma
7
Pipeline Programs↗
12
Active Trials↗
6
Companies Involved↗
Thyroid Carcinoma is an early-stage landscape with 7 programs across 6 companies. 1 program is in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Pipeline
Programs by Phase
Preclinical4
Phase 11
Phase 21
Approved
No programs
Analysis
Modality Breakdown
83%
Small molecule
5 of 6 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 6 classified programs, each share of the total. Modality classified for 86% of 7 pipeline programs.
Analysis
Trial Status
29
clinical trials
Recruiting9 · 31%
Completed8 · 28%
Unknown status5 · 17%
Terminated3 · 10%
Active, not recruiting2 · 7%
Withdrawn1 · 3%
Other1 · 3%
Clinical Trials
Trial Activity
29 trials
The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer
Recruiting·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT04927416·54 enrolled
Clinical and Genetic Studies in Familial Non-Medullary Thyroid Cancer
Recruiting·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·N/A·NCT01109420·500 enrolled
Studies on Thyroid Nodules and Thyroid Cancer
Recruiting·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·N/A·NCT00001160·2,500 enrolled
Combination Radiotherapy and Radiopharmaceutical Therapy Treatment Planning for Thyroid Cancer
Recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT04892303·48 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)